GENE ONLINE|News &
Opinion
Blog

Regeneron Secures $4.5 Billion Worth of Contracts from the US for Combating COVID-19

by GeneOnline
Share To

By Vicky Su

On July 7th, 2020, Regeneron Pharmaceuticals, Inc. announced that the Trump administration has awarded them a $4.5 billion contract to manufacture and supply REGN-COV2, an investigational antibody cocktail for COVID-19.

REGN-COV2 is a novel double-antibody drug cocktail developed by Regeneron. The two virus-neutralizing antibodies in the cocktail can recognize and bind to the receptor of the critical spike protein that SARS-COV-2 uses to enter cells. Similar to the cocktail therapy concept used for HIV prevention, the double-antibody could protect against viral escape and achieve antiviral effects.

In mid-June 2020, Regeneron launched the first REGN-COV2 clinical trial, aiming to test the ability to treat and prevent coronavirus. Four cohorts were recruited; hospitalized and non hospitalized symptomatic COVID-19 patients, as well as uninfected people such as healthcare workers with high exposure risk, and uninfected people exposed to COVID-19 (such as the patient’s roommates).

On July 6th, the company announced the initiation of its late-stage trials. A Phase 3 trial will evaluate REGN-COV2’s ability to prevent COVID-19, which is expected to recruit 2,000 uninfected subjects in close contact with COVID-19 patients. The trial will be conducted in 100 different locations.

REGN-COV2 has also moved to the Phase 2/3 section that evaluates the cocktail’s ability to treat hospitalized and non-hospitalized (or “ambulatory”) patients with COVID-19. The trial will recruit about 1,850 inpatients and 1,050 non-inpatients (e.g., outpatients), and conducted in approximately 150 regions in the United States, Brazil, Mexico, and Chile.

Besides, these ongoing clinical trials are also aiming to identify the most suitable dose. Regeneron is expected to release the drug by the end of the summer. The US government has promised that if the drug notches an emergency FDA authorization for both the prevention and treatment o COVID-19, it will be distributed to the people free of charge.

“This agreement with Regeneron is the first of several Operation Warp Speed awards to support potential therapeutics through large scale manufacturing, allowing faster distribution if trials are successful,” said HHS Secretary Alex Azar.

Editor: Sherry Hsiao

Related Article: COVID-19: Discovery of New Spike Protein Neutralizing Antibody Reveals Promising Drug Target

References
  1. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention
  2. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-manufacturing-and-supply-agreement-barda-and

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top